Conference Correspondent

Results from the ARCHER 1009 Study: Dacomitinib Versus Erlotinib for Second-/Third-Line Therapy of Locally Advanced or Metastatic NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent — June 2, 2014

Results from PROFILE 1014: First-Line Crizotinib Versus Pemetrexed-Platinum in ALK+ NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent — June 2, 2014

Erlotinib Plus Bevacizumab as First-Line Treatment for EGFR+, Advanced NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent — June 2, 2014

Adjuvant Ipilimumab for Patients with High-Risk Melanoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent — June 2, 2014

First Trial Assessing Nivolumab in Platinum-Resistant Ovarian Cancer

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent — June 1, 2014

Phase 2 Trial of Nivolumab in Metastatic Renal Cell Carcinoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent — June 1, 2014

Phase 2 Trial of Nivolumab and VEGF Inhibitors in First-Line Metastatic Renal Cell Carcinoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent — June 1, 2014

MPDL3280A, an Anti-PD-L1 Monoclonal Antibody, in Metastatic Bladder Cancer

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent — June 1, 2014

Chemotherapy Plus Bevacizumab or Cetuximab in mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent — June 1, 2014

Racial Differences in KRAS/BRAF Mutation Rates and Survival in mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent — June 1, 2014

Page 40 of 44

37
38
39
40
41
42
43